FAPI PET/CT在胆囊癌评估中展现良好潜力:一项前瞻性研究对比[68Ga]Ga-FAPI-04与[18F]FDG
这项前瞻性研究纳入22例原发性或复发性胆囊癌患者,在一周内分别行[68Ga]Ga-FAPI-04与[18F]FDG PET/CT,比较两者对原发灶、远处转移、淋巴结转移和腹膜转移的检出能力与摄取差异。结果显示FAPI在原发灶TBR、远处转移和淋巴结转移的检出率及SUVmax、TBR方面优于FDG,并促使4例患者分期发生改变。
要点
- FAPI在原发灶TBR显著高于FDG(15.97±9.70 vs 5.96±3.14,p=0.001)。
- FAPI对远处转移和淋巴结转移的检出率及SUVmax、TBR均高于FDG。
- FAPI检出腹膜受累病灶的SUVmax更高,并促使2例升期、2例降期。
核心结论
- [68Ga]Ga-FAPI-04在检测胆囊癌原发肿瘤、远处转移、淋巴结转移和腹膜转移方面优于[18F]FDG,表现为更高的SUVmax值和TBR比值。
- [68Ga]Ga-FAPI-04在胆囊癌分期和筛选放射性核素靶向治疗患者方面显示出应用前景。
研究设计与样本
- 前瞻性研究,纳入根据超声、MRI和PET/CT评估诊断为原发性或复发性胆囊癌的患者。
- 所有患者在一周内分别接受[68Ga]Ga-FAPI-04和[18F]FDG PET/CT两次扫描。
- 共纳入22例患者(年龄60.18±9.53岁;男11例,女11例)。
主要发现
- [68Ga]Ga-FAPI-04与[18F]FDG对原发性胆囊癌病灶的检出率和SUVmax相当。
- [68Ga]Ga-FAPI-04在原发肿瘤的TBR显著更高(15.97±9.70 vs. 5.96±3.14,95%CI [4.78,15.23],p=0.001)。
- [68Ga]Ga-FAPI-04在远处转移的检出率更高(100% vs. 80%),SUVmax为8.88[5.53, 11.83] vs. 5.34[3.35, 9.80](95%CI [1.93,4.25],p<0.001),TBR为11.18[5.64, 14.97] vs. 6.11[3.48, 12.75](95%CI [7.46,11.15],p<0.001)。
- [68Ga]Ga-FAPI-04在淋巴结转移的检出率更高(99% vs. 94%),SUVmax为8.85[6.58, 11.20] vs. 6.00[4.24, 8.03](95%CI [2.44,3.43],p<0.001),TBR为15.90[10.31, 20.41] vs. 9.96[6.09, 14.37](95%CI [6.19,8.43],p<0.001)。
- [68Ga]Ga-FAPI-04检出腹膜受累病灶的SUVmax值更高;最终2例患者基于[68Ga]Ga-FAPI-04结果分期上调,2例分期下调。
临床怎么用
- 对于胆囊癌患者,可考虑使用[68Ga]Ga-FAPI-04 PET/CT评估原发灶、远处转移、淋巴结转移和腹膜转移,以辅助分期。
- [68Ga]Ga-FAPI-04的高TBR和SUVmax可能有助于筛选适合放射性核素靶向治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate staging of gallbladder cancer (GBC) is crucial for treatment planning. [18F]FDG PET/CT is limited in evaluating GBC due to high liver background signal and difficulty distinguishing inflammatory from malignant lesions. [68Ga]Ga-FAPI-04 PET/CT offers high tumor uptake and tumor-background contrast, demonstrating significant value in assessing multiple tumor types. This study aimed to investigate the value and the impact on clinical staging management of [68Ga]Ga-FAPI-04 comparing with [18F]FDG PET/CT in patients with gallbladder cancer. METHODS: This prospective study included patients diagnosed with primary or recurrent gallbladder cancer based on ultrasound, MRI, and PET/CT evaluations. All patients underwent two scans with [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT within one week. The study compared the detection capabilities and uptake (SUVmax and TBR) differences of both tracers in primary tumors, distant metastases, lymph nodes, and peritoneal metastases. RESULTS: This study included 22 patients (age: 60.18 ± 9.53; 11 male, 11 female). [68Ga]Ga-FAPI-04 and [18F]FDG demonstrated comparable detection rates and maximum standardized uptake values (SUVmax) for primary gallbladder cancer lesions. However, [68Ga]Ga-FAPI-04 demonstrated significantly higher tumor-to-background ratios (TBR) in primary tumors (15.97 ± 9.70 vs. 5.96 ± 3.14, 95%CI [4.78,15.23], p=0.001). Higher detection rates (100% vs. 80%; 99% vs. 94%, respectively) and maximum standardized uptake values were observed for [68Ga]Ga-FAPI-04 in distant metastases and lymph node metastases (distant metastases: 8.88[5.53, 11.83] vs. 5.34[3.35, 9.80], 95%CI [1.93,4.25], p<0.001; lymph node metastasis: 8.85 [6.58, 11.20] vs. 6.00 [4.24, 8.03], 95%CI [2.44,3.43], p<0.001) and TBR values (distant metastasis: 11.18 [5.64, 14.97] vs. 6.11 [3.48, 12.75], 95%CI [7.46,11.15], p<0.001; Lymph node metastasis: 15.90 [10.31, 20.41] vs. 9.96 [6.09, 14.37], 95%CI [6.19,8.43], p<0.001). Additionally, [68Ga]Ga-FAPI-04 detected lesions in peritoneal involvement with higher SUVmax values. Ultimately, two patients had their staging upgraded based on [68Ga]Ga-FAPI-04 results, while two others had their staging downgraded. CONCLUSIONS: [68Ga]Ga-FAPI-04 outperformed [¹⁸F]FDG in detecting primary gallbladder cancer tumors, distant metastases, lymph node metastases, and peritoneal metastases, demonstrating higher SUVmax values and TBR ratios. Additionally, [68Ga]Ga-FAPI-04 shows promise in staging gallbladder cancer and selecting patients for radionuclide-targeted therapy.
引用
- Peng D, Cheng K, Xu T, et al. FAPI PET/CT shows favorable potential for the evaluation of gallbladder cancer: a prospective study comparing [68Ga]Ga-FAPI-04 and [18F]FDG. EJNMMI Res. 2026. PMID: 42010112. doi:10.1186/s13550-026-01434-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。